Abolish the FDA
It takes 10–15 years and hundreds of millions of dollars for a pharmaceutical company to navigate the Food and Drug ...
News Medical18h
The benefits and challenges of FDA Fast-Track and Accelerated Approval in drug development
The FDA Fast Track process features regular interactions with the FDA, including the potential for early and rolling review ...
WBRC FOX6 News21h
FDA bans certain synthetic dye from cosmetics but allows in food, advocate calls it ‘illogical’
“The FDA recognizes that there’s a problem, so they have begun to formulate a plan to put a system in place, and they made ...
After decades, FDA finally moves to pull ineffective decongestant off shelves
In a long-sought move, the Food and Drug Administration on Thursday formally began the process of abandoning oral doses of a ...
FiercePharma3h
GAO takes FDA to task over lagging plant inspections, recommends action plan
“FDA has not yet developed action plans to fully address travel, workload, and work-life balance because potential solutions ...
Ligand engineering method streamlines design for chemical reactions in catalysis and drug delivery
Researchers at Hokkaido University in Japan have developed a technique called Virtual Ligand-Assisted Optimization, or VLAO, ...
Acsh.org16h
The Media and I: Hurricane Helene and Drug Shortages
Our conversation turned to the FDA's approval process, where I shared my frustration over unnecessary delays. Conversely, the ...
Reuters17h
US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder
The drugmaker will also get the FDA's priority review voucher, which allows a drug developer to expedite the review process ...
Researcher Sues DEA Over Marijuana Rescheduling Process
A researcher has filed a lawsuit against the Drug Enforcement Administration, accusing the agency of multiple legal ...
ConsumerAffairs6d
FDA proposes removing popular decongestant found in cold meds
The Food and Drug Administration (FDA) is proposing to officially remove a popular ingredient in many cold and allergy ...
BioPharma Dive2d
FDA approves new CAR-T competitor to Gilead’s Tecartus
Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...